The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes and obesity, respectively.

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded drugs — not be false or misleading,” contended Pharmaceutical Research and Manufacturers of America (PhRMA), whose public affairs team invited reporters to “reach out if you have any questions.”

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto against weight-loss treatments priced “for profits, not patients,” after critici

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss offerings in a way that will generate buzz.

The ad from the telehealth company Hims & Hers promoted the company’s compounded weight loss drugs. The ad portrayed the obesity epidemic as a rigged game because of the greedy health care system. Dr.